research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.